Effects of omega-3 fatty acids supplementation on neoadjuvant chemotherapy-induced toxicity in patients with locally advanced breast cancer: A randomized, controlled, double-blinded clinical trial
Por:
de la Rosa Oliva F., García A.M., Calzada H.R., Astudillo de la Vega H., Rocha E.B., Lara-Medina F., Alvarado-Miranda A., Matus-Santos J., Flores-Díaz D., Oñate-Acuña L.F., Gutiérrez-Salmeán G., Ruiz-García E., Ibarra A.
Publicada:
1 ene 2019
Resumen:
Background: antineoplastic treatment for locally advanced breast cancer (LABC) includes neodjuvant chemotherapy (NeoCT). However, side effects occur frequently, affecting the functional capacity and quality of life of patients as a result of the proinflammatory state of this therapy. In this work, omega-3 polyunsaturated fatty acids (PUFA O-3) were administered as they have been reported to modulate some molecular pathways such as nuclear factor-kappa B (NF-?B), which is associated with toxicity secondary to the administration of anthracyclines. Objective: to evaluate the effects of PUFA O-3 on the toxicity, side effects, body composition, cardiometabolic profile and quality of life in women with LABC after NeoCT. Methods: fifty-three women with LABC were included in a double-blinded, placebo-controlled clinical trial. Patients randomly received 2.4 g/day of PUFA O-3 (EPA 1.6 g and DHA 0.8 g) or placebo during NeoCT with adriamycin/cyclophosphamide followed by paclitaxel+/-trastuzumab. Adverse effects related to chemotherapy were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE, version 4.03) and the Subjective Global Scale of the Edmonton Symptom Assessment System (ESAS). Body composition and cardiometabolic blood profile were also evaluated. Results: no significant differences were found between groups in the hematological and anthropometric toxicity parameters. Within the Edmonton scale, xerostomia presented a significant improvement (p = 0.032) in patients supplemented with PUFA O-3. Conclusion: supplementation with PUFA O-3 showed no change in body composition, cardiometabolic profile or toxicity due to NeoCT. It only showed significant improvement in xerostomia. © 2019, ARAN Ediciones S.A. All rights reserved.
Filiaciones:
de la Rosa Oliva F.:
Laboratorio de Medicina Traslacional, Instituto Nacional de Cancerología, Ciudad de México, Mexico
Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac México Campus Norte, Huixquilucan, Mexico
Universidad Autónoma de Zacatecas, Zacatecas, Mexico
García A.M.:
Laboratorio de Medicina Traslacional, Instituto Nacional de Cancerología, Ciudad de México, Mexico
Calzada H.R.:
Universidad Autónoma de Zacatecas, Zacatecas, Mexico
Hospital General No. 26 ISSSTE Zacatecas, Zacatecas, Mexico
Astudillo de la Vega H.:
Laboratorio de Investigación Traslacional y Terapia Celular, Hospital de Oncología CMN SXXI-IMSS, Ciudad de México, Mexico
Rocha E.B.:
Departamento de Tumores Mamarios, Instituto Nacional de Cancerología, Ciudad de México, Mexico
Lara-Medina F.:
Departamento de Tumores Mamarios, Instituto Nacional de Cancerología, Ciudad de México, Mexico
Alvarado-Miranda A.:
Departamento de Tumores Mamarios, Instituto Nacional de Cancerología, Ciudad de México, Mexico
Matus-Santos J.:
Departamento de Tumores Mamarios, Instituto Nacional de Cancerología, Ciudad de México, Mexico
Flores-Díaz D.:
Laboratorio de Investigación Traslacional y Terapia Celular, Hospital de Oncología CMN SXXI-IMSS, Ciudad de México, Mexico
Oñate-Acuña L.F.:
Laboratorio de Investigación Traslacional y Terapia Celular, Hospital de Oncología CMN SXXI-IMSS, Ciudad de México, Mexico
Gutiérrez-Salmeán G.:
Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac México Campus Norte, Huixquilucan, Mexico
Ruiz-García E.:
Laboratorio de Medicina Traslacional, Instituto Nacional de Cancerología, Ciudad de México, Mexico
Ibarra A.:
Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac México Campus Norte, Huixquilucan, Mexico
|